Merck & Co., Inc. $MRK Stock Holdings Reduced by Capital Investment Advisors LLC

Capital Investment Advisors LLC cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 41.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 219,765 shares of the company’s stock after selling 156,799 shares during the quarter. Capital Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $31,934,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Bullseye Investment Management LLC acquired a new position in Merck & Co., Inc. during the second quarter valued at $27,000. Curry Webb Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $29,000. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $30,000. Graney & King LLC raised its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $41,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Merck & Co., Inc. Stock Down 1.4%

NYSE:MRK opened at $145.25 on Friday. The firm has a market capitalization of $358.35 billion, a PE ratio of 116.20, a price-to-earnings-growth ratio of 6.83 and a beta of 0.21. The stock has a 50 day moving average of $146.98 and a 200-day moving average of $130.17. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Insider Transactions at Merck & Co., Inc.

In other news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last three months. 0.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Argus upped their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, October 5th. Cantor Fitzgerald raised their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Citigroup raised their price target on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, October 12th. Finally, Guggenheim lifted their price objective on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.